【野村升翰森制药目标价2%至18.36港元 维持中性评级】金十数据2月26日讯，野村发表报告，将翰森制药(03692.HK)目标价从17.95港元上调2%至18.36港元，反映下跌空间为3.2%，维持中性评级。该行预计2024下半年收入将下跌0.5%，盈利将按年减35%。该行将2024财年收入及盈利预测下调0.6%及4.2%，将2025财年收入及盈利预测上调4.5%及1.8%，考虑因素包括向MSD授权HS-10535(口服GLP-1资产)而获合作收入，以及销售业绩优于预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.